NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics today said that it completed its $12 million Series B equity financing round to support the commercial expansion of its RNA biomarker technology.

New Leaf Venture Partners and existing investor Morningside Ventures participated in the round.

The funding will go toward further commercialization of Advanced Cell's RNAscope-based products and services into the life science research market, as well as toward acceleration of RNAscope into the clinical diagnostics space.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.